Biography of Dr. Masood Khan
Masood Khan

Dr. Masood Khan



Dr. Masood Khan is Vice President at Alliance Pharma in Malvern, Pennsylvania. He heads up the Biopharmaceutical Services division of the company and oversees a team of scientists involved in assay development, validation, and application of a wide variety of ligand-binding assays (LBA) for pharmacokinetics, toxicokinetics, immunogenicity, and biomarker assessment in preclinical and clinical studies. Previously, he served in executive capacities at several major contract research organizations and pharmaceutical companies, including Phoenix International Life Sciences, NeuroBiotech, Medlmmune, Covance, and KCAS.

Dr. Khan has a world-renowned reputation as a thought leader and a mentor in the field of regulatory compliant LBAs. He is active contributor to the scientific activities at GCC, WRIB and AAPS. He is a founding member of the LBA Bioanalytical Focus Group (LBABFG) where he actively served on the steering committee for over 8 years. He played an active role in the formation of the Biomarker Discussion Group (BDG) (formerly Biomarker Action Plan Committee) in 2007 and served as LBABFG steering committee sponsor of BDG for several years. In recent years, he served on several BDG subcommittees geared toward producing white papers related to the Multiplex Biomarker Assay Validation, Biomarker Sample Stability Considerations, and recommendations on creation of pharmaceutical grade kits for biomarkers. From 2013 to 2014, he led the Commercial Biomarker Kit Validation subcommittee and published a white paper, "Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development" in the journal of Bioanalysis (January 2015). To date, Dr. Khan has over 120 publications and presentations, including several other white papers and a book entitled, Ligand Binding Assays: Development, Validation, and Implementation in the Drug Development Arena (2009), a consolidated and comprehensive reference widely used in the pharmaceutical industry.